# Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans

> **NCT02117206** · PHASE4 · COMPLETED · sponsor: **University Hospital, Strasbourg, France** · enrollment: 60 (actual)

## Conditions studied

- Skeletal Muscle Ischemia
- Severe Lower Limb Ischemia
- Mitochondrial Dysfunction

## Interventions

- **DRUG:** L-arginine (L-arginine Veyron)
- **DRUG:** Nacl

## Key facts

- **NCT ID:** NCT02117206
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2012-03
- **Final completion:** 2013-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117206, "Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02117206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*